目的：回顧過去十五年(1979-1993)在臺大醫院惡性鼻咽淋巴瘤之治療成果。材料與方法：這十五年中臺大醫院共有 40 位惡性鼻咽淋巴瘤之病患。年齡分佈自 13 至 81 歲，男、女性病患各 20 位。第一、二期各有 18 及 22 個病例。以組織病理學而言，低、中、高級各有 10、26 及 4 位. 7 位病患只接受傴射治療， 15 位病患只接受化學治療， 10位病患接受放射及化學合併治療，8 位病患未接受任何治療。結果：第一、二期五年存活率分別為 65.7% 及 27.3%。 以 Rappaport 分類法時， 結節性與瀰漫性五年存活率分別為722.7% 及 33.5%； 以 Working formulation 分類時， 低、 中、 高級五年存活率分別為80.0%， 39.0% 及 50.0%。 放射治療，化學治療及合併療法之五年存活率分別為 100.0%，58.7% 及 30.0%。結論：淋巴瘤局限於鼻咽之淋巴瘤可用放射治療加以控制。以組織病理學分類時，低級或結節性之惡性鼻咽淋巴瘤可單獨使用放射治療。而中級或瀰漫性之惡性鼻咽淋巴瘤使用化學治療或合併療法， 對病患之存活率則有所俾益。 [ 放射治療與腫瘤學1997;4:85-91]five-year survival rates for nasopharyngeal malignantlympoma patients with Stage I, II were 65.7% and 27.3%, respectively. Whenclassified by the Rappaport classification, the actuarial five-year survivalrates for patients of nodular type and diffuse type were 72.7% and 33.5%,respectively. The actuarial five-year survial rates for patients of low grade,intermediate grade and high grade nasopharyngeal malignant lymphoma were 80.0%,39.0%, and 50.0%, repectively. The actuarial five-year survival rates forpatients treated with radiotherapy, chemotherapy and combined treatmentmodalities were 100.0%, 58.7%, and 30.0% respectively. Conclusion: Lymphomaclinically localized to nasopharnx can be cured by radiotherapy. When classifiedby histopathology, patients with low grade or nodular type can be successfullytreated using local radiotherapy alone. Chemotherapy used as primary treatment(with or without adjuvant radiotherapy) may be benfit for intermediate grade ordiffuse type patients. [Therapeut Radiol Oncol 1997; 4:85-91]